Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current developments in thrombolytic therapy using novel plasminogen activators.

E Seifried1, P Tanswell

  • 1Abteilung Innere Medizin III, Medizinische Klinik und Poliklinik der Universität Ulm, Fed. Rep. of Germany.

Arzneimittel-Forschung
|November 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Superior physical and mental health of healthy volunteers before and five years after mobilized stem cell donation.

Journal of translational medicine·2022
Same author

Novel method for reduction of virus load in blood plasma by sonication.

European journal of medical research·2020
Same author

Enlargement of the WHO international repository for platelet transfusion-relevant bacteria reference strains.

Vox sanguinis·2017
Same author

Patient Blood Management in Europe: surveys on top indications for red blood cell use and Patient Blood Management organization and activities in seven European university hospitals.

Vox sanguinis·2016
Same author

Pathogen-reduced Ebola virus convalescent plasma: first steps towards standardization of manufacturing and quality control including assessment of Ebola-specific neutralizing antibodies.

Vox sanguinis·2016
Same author

Four amino acid exchanges located in the alpha-2 domain specify the novel HLA-B*50:20 allele.

Tissue antigens·2015
Same journal

Wirksamkeit und Verträglichkeit eines pflanzlichen Arzneimittels mit Kapuzinerkressenkraut und Meerrettich bei akuter Sinusitis, akuter Bronchitis und akuter Blasenentzündung im Vergleich zu anderen Therapien unter den Bedingungen der täglichen Praxis.

Arzneimittel-Forschung·2013
Same journal

Abstracts of the Paul-Martini-Stiftung Symposium 2012 in combination with the National Academy of Leopoldina. November 16-17, 2012. Berlin, Germany.

Arzneimittel-Forschung·2013
Same journal

Leave-one-out procedure in the validation of elimination rate constant analysis.

Arzneimittel-Forschung·2012
Same journal

Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients.

Arzneimittel-Forschung·2012
Same journal

Synthesis, anti-hypertensive effect of a novel angiotensin II AT1 receptor antagonist and its anti-tumor activity in prostate cancer.

Arzneimittel-Forschung·2012
Same journal

Effect of zeolite nano-materials and artichoke (Cynara scolymus L.) leaf extract on increase in urinary clearance of systematically absorbed nicotine.

Arzneimittel-Forschung·2012
See all related articles

New fibrin-specific thrombolytic agents like recombinant tissue-type plasminogen activator (rt-PA) show superior efficacy in treating myocardial infarction. Further research focuses on developing next-generation agents for improved thrombolysis.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • The human fibrinolytic system's molecular mechanisms have been elucidated through recent research.
  • Therapeutic thrombolysis using streptokinase and urokinase is established for thromboembolic diseases.
  • There is a need for fibrin-specific thrombolytic agents with high potency and minimal systemic hemostasis effects.

Purpose of the Study:

  • To review the development and efficacy of fibrin-specific thrombolytic agents.
  • To compare the clinical performance of recombinant tissue-type plasminogen activator (rt-PA) and pro-urokinase.
  • To discuss future directions in thrombolytic agent development.

Main Methods:

  • Review of clinical trials and scientific literature on thrombolytic therapy.

Related Experiment Videos

  • Analysis of mechanisms of action and efficacy of rt-PA and pro-urokinase.
  • Examination of bleeding complications and laboratory monitoring in thrombolysis.

    • Main Results:

    • Intravenous rt-PA demonstrates superior efficacy in myocardial infarction treatment compared to conventional agents.
    • Pro-urokinase has been less extensively studied clinically.
    • Fibrin specificities of therapeutic agents differ, and bleeding complications are not clearly correlated with hemostasis parameters.
    • Fibrinogen and thrombin clotting time are recommended for laboratory monitoring.

    Conclusions:

    • rt-PA is a highly effective fibrin-specific thrombolytic agent for myocardial infarction.
    • Next-generation thrombolytic agents include mutants, chimeras, and antibody conjugates of t-PA and pro-urokinase.
    • Continued research aims to enhance thrombolytic potency and specificity while minimizing bleeding risks.